Showing results (1611-1620 of 1,659) with videos related to

Sort By:
Pageof 166
Circulation. Genomic and Precision Medicine|September 30, 2022
Genetic Evaluation of A Nation-Wide Dutch Pediatric DCM Cohort: The Use of Genetic Testing in Risk StratificationMarijke H van der Meulen, Johanna C Herkert, Susanna L den Boer, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 31, 2025
Kidney replacement therapy for men and women according to the ERA Registry and the USRDSVianda S Stel, Nicholas C Chesnaye, Rianne Boenink, et al.
Research and Practice in Thrombosis and Haemostasis|April 10, 2025
The impact of pulmonary embolism on health outcomes of COVID-19 at 3 months after hospitalizationChantal Visser, Julia C Berentschot, Cindy M M de Jong, et al.
Science Translational Medicine|June 14, 2019
A systems genomics approach identifies SIGLEC15 as a susceptibility factor in recurrent vulvovaginal candidiasisM Jaeger, M Pinelli, M Borghi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 18, 2020
Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based StudyMichiel C T van Zeijl, John B A G Haanen, Michel W J M Wouters, et al.
Nature|November 20, 1980
A new class of angiotensin-converting enzyme inhibitorsA A Patchett, E Harris, E W Tristram, et al.
Nederlands Tijdschrift Voor Geneeskunde|July 25, 2018
[Recent treatment results for metastatic melanoma: data from the Dutch Melanoma Treatment Registry]Michiel C T van Zeijl, Alfons J M van den Eertwegh, Michel W J M Wouters, et al.
American Journal of Clinical Oncology|December 17, 2020
Nationwide Outcomes of Advanced Melanoma According to BRAFV600 StatusJesper van Breeschoten, Michel W J M Wouters, Liesbeth C de Wreede, et al.
British Journal of Cancer|January 26, 2021
First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysisJesper van Breeschoten, Michel W J M Wouters, Doranne L Hilarius, et al.
Lancet (London, England)|April 12, 2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer GroupLieke H J Simkens, Harm van Tinteren, Anne May, et al.
Pageof 166